See more : X Financial (XYF) Income Statement Analysis – Financial Results
Complete financial analysis of Gelesis Holdings, Inc. (GLS-WT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gelesis Holdings, Inc., a leading company in the industry within the sector.
You may be interested
- Earum Pharmaceuticals Limited (EARUM.BO) Income Statement Analysis – Financial Results
- Elite Advanced Laser Corporation (3450.TW) Income Statement Analysis – Financial Results
- C4X Discovery Holdings plc (C4XD.L) Income Statement Analysis – Financial Results
- Kabsons Industries Limited (KABSON.BO) Income Statement Analysis – Financial Results
- Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) Income Statement Analysis – Financial Results
Gelesis Holdings, Inc. (GLS-WT)
Metric | 2022 | 2021 |
---|---|---|
Revenue | 25.77M | 11.19M |
Cost of Revenue | 27.56M | 9.98M |
Gross Profit | -1.79M | 1.20M |
Gross Profit Ratio | -6.95% | 10.75% |
Research & Development | 18.61M | 12.87M |
General & Administrative | 42.21M | 18.26M |
Selling & Marketing | 56.92M | 52.78M |
SG&A | 99.14M | 71.04M |
Other Expenses | 2.27M | 2.27M |
Operating Expenses | 120.02M | 86.18M |
Cost & Expenses | 147.57M | 96.16M |
Interest Income | 0.00 | 0.00 |
Interest Expense | 991.00K | 1.36M |
Depreciation & Amortization | 7.59M | 4.44M |
EBITDA | -121.81M | -80.53M |
EBITDA Ratio | -443.25% | -719.97% |
Operating Income | -121.81M | -84.97M |
Operating Income Ratio | -472.72% | -759.70% |
Total Other Income/Expenses | 66.51M | -8.36M |
Income Before Tax | -55.30M | -93.33M |
Income Before Tax Ratio | -214.62% | -834.42% |
Income Tax Expense | 480.00K | 17.00K |
Net Income | -55.78M | -93.35M |
Net Income Ratio | -216.48% | -834.57% |
EPS | -0.79 | -16.34 |
EPS Diluted | -0.79 | -16.34 |
Weighted Avg Shares Out | 70.30M | 5.71M |
Weighted Avg Shares Out (Dil) | 70.30M | 5.71M |
No news found for: GLS-WT
Source: https://incomestatements.info
Category: Stock Reports